Vinod Metta, Huzaifa Ibrahim, Neha Muralidharan, Kislyn Rodriguez, Therese Masagnay, Judith Mohan, Arlet Lacsina, Abdullah Ahmed, Hani T S Benamer, Guy Chung-Faye, Rukmini Mrudula, Cristian Falup-Pecurariu, Carmen Rodriguez-Blazquez, Rupam Borgohain, Vinay Goyal, Kalyan Bhattacharya, K Ray Chaudhuri
Parkinson's disease (PD) is the second most common neurodegenerative disorder, and the condition is complicated by the emergence of wearing off/motor fluctuations with levodopa treatment after a variable period. COMT inhibitors when used as adjunct therapy to levodopa tend to smoothen out these wearing off fluctuations by enhancing delivery of levodopa and increasing its bioavailability to the brain. The study was conducted to investigate the motor and nonmotor effect, safety and tolerability of the third generation once-daily COMT inhibitor (opicapone), as add-on, adjuvant therapy to levodopa and at 6 and 12 months follow-up in a real-life cohort of consecutive Emirati and non-White PD patients...
October 5, 2023: Journal of Neural Transmission